Free Biopharma Daily Stock Updates - 05/24/21

$XBI $126 -1%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$MRNA +2% Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline. source

$TLC +16% InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19. source

$NVAX +2% Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea. source

$MRNA +2% Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine. source

Pipeline Updates

$VSTM +25% Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer. source

$EXEL -3% Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. source

$SRRK +5% Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy. source

$SUPN -1% Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age. source

$VERU -1% Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. source

$PDSB +7% PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting. source

$SPRB -6% Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology. source

$IRWD -1% More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW). source

$CLNN -2% Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement. source

$OPK +3% OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor. source

$AXLA -6% Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021. source

$XERS -6% $SBBP +10% Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases. source

$PTGX +3% Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232. source

$ALLK -1% New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms. source

$NGM -40% NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH. source

---

Posted by FS/DV